Key Highlights
- Arcus shares ticked up 0.41% to $15.85, against a prior close of $15.78.
- The stock sits near its 52-week low of $15.63.
- Third-quarter Revenue was $9 million, down from $26 million a year earlier.
- The company priced a $250 million stock offering in October.
- The consensus target is about $41.
Strong Kidney Cancer Data Meets a Weak Share Price
Arcus Biosciences (NYSE:RCUS) shares ticked up 0.41% to $15.85 on Friday, on Volume of about 705,540 shares, near the 52-week low of $15.63. Investors are weighing strong casdatifan data in kidney cancer and a cash runway into 2029 against a post-offering slide, shrinking collaboration revenue and a weak risk backdrop.
Arcus is a clinical-stage biotechnology company with a net loss per share of $3.90 over the past year.
Wider Third-Quarter Loss and a $250 Million Offering
The company priced a $250 million stock offering in October and reported a third-quarter loss of $1.00 per share, wider than expected, on revenue of $9 million, down from $26 million a year earlier.
Analyst targets remain far above the share price. The consensus is about $41, and Leerink raised its target to $49.
Conferences and PEAK-1 Enrollment Are the Next Markers
Management will present at conferences on Dec. 1 and 2, and enrollment in the Phase 3 PEAK-1 trial is expected to finish within two to three months.
Biotech peers were mixed. Arcutis Biotherapeutics (NASDAQ:ARQT) fell 1.73%, Legend Biotech (NASDAQ:LEGN) dropped 4.72%, Xencor (NASDAQ:XNCR) slipped 1.17% and Beam Therapeutics (NASDAQ:BEAM) gained 2.01%. The 52-week range runs from $15.63 to $31.74.
PEAK-1 Enrollment Completion Could Reset the Narrative
Arcus trades near its low despite clinical progress and a funded runway. Investors will watch the December conferences and completion of PEAK-1 enrollment.
_11_20_2026_19_30_07_879097.jpg)

_11_20_2026_19_32_49_884922.jpg)



Please wait processing your request...